Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.2M | $23.4M | $50.5M | $146M | $225M | $147M | $197M |
| Revenue growth | — | -24.9% | 115.6% | 189.2% | 54.1% | -34.8% | 34.3% |
| Gross profit | — | — | — | — | — | $29.6M | $41.1M |
| Gross margin | — | — | — | — | — | 20.2% | 20.9% |
| Operating income | -$11.5M | -$10.4M | -$24.1M | -$53.5M | -$68.1M | -$22.5M | -$22.4M |
| Operating margin | -37.0% | -44.2% | -47.7% | -36.6% | -30.3% | -15.3% | -11.3% |
| Net income | -$10.8M | -$10.2M | -$40.1M | -$27.3M | -$56.1M | -$27.3M | $41.3M |
| Net margin | -34.7% | -43.4% | -79.3% | -18.7% | -24.9% | -18.6% | 21.0% |
| EPS (diluted) | -$0.43 | -$0.40 | -$0.93 | -$0.38 | -$0.76 | -$0.35 | $0.50 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.3M | -$10.8M | -$15.6M | -$37.1M | -$32.3M | -$2.52M | -$48.9M |
| Capital expenditures | $604K | $377K | $297K | $730K | $2.11M | $30.9M | $9.60M |
| Free cash flow | -$10.9M | -$11.2M | -$15.9M | -$37.9M | -$34.5M | -$33.4M | -$58.5M |
| Share buybacks | — | — | — | — | $0.00 | $244K | $0.00 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.2M | $12.2M | $6.95M | $41.3M | $27.9M | $18.4M | $31.0M |
| Total assets | $278M | $17.7M | $336M | $325M | $295M | $257M | $325M |
| Total liabilities | $10.00M | $6.63M | $44.5M | $50.5M | $60.6M | $34.7M | $46.4M |
| Long-term debt | — | — | — | $0.00 | — | — | — |
| Shareholders' equity | $20.7M | $11.1M | $291M | $274M | $234M | $222M | $279M |
| Retained earnings | $785K | -$37.1M | -$76.4M | -$104M | -$160M | -$187M | -$146M |
| Shares (wtd avg diluted) | 25.1M | 25.2M | 42.9M | 71.2M | 73.5M | 77.5M | 82.1M |
Every figure is extracted from Strata Critical Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.